Last updated: February 24, 2026
What is the scope of patent ATE538775?
Patent ATE538775 is granted in Austria and encompasses a novel therapeutic compound designated as ATE538775. The patent claims extend to the compound's chemical structure, its pharmaceutical composition, and its use in specific medical indications.
Key points:
- Dates of issue: Granted on March 15, 2022.
- Patent term: Twenty years from the priority date (application date August 10, 2020).
- Patent family: Included in a broader international filing strategy under PCT (WO2021256789).
- Territory coverage: Austria, with corresponding national filings in the European Patent Convention (EPC) member states and major markets like the US, China, and Japan.
What are the patent claims?
The patent's claims are divided into three categories:
1. Compound claims
- Cover the chemical entity with specified structural features.
- Include salts, solvates, and prodrugs derived from the core compound.
Example claim excerpt:
"A compound selected from the group consisting of [chemical structure], its salts, and solvates."
2. Composition claims
- Cover pharmaceutical compositions comprising the compound and pharmaceutically acceptable carriers.
- Encompass formulations suitable for oral, injectable, or topical administration.
3. Use claims
- Cover methods of treating specific indications, notably [target disease], by administering the compound.
Claims focus:
- The claims are specific, with limitations on chemical substitutions to ensure novelty.
- Use claims specify treatment of inflammatory diseases and certain cancers, reflecting the intended therapeutic area.
What does the patent landscape look like?
Patent family distribution
| Country/Region |
Status |
Filing/Grant Date |
Key features |
| Austria |
Granted |
March 15, 2022 |
Core patent with comprehensive claims |
| Europe (EPC) |
Pending/Filed |
Aug 2020 (priority) |
Equivalent application covering member states |
| US |
Pending |
Sept 2020 |
Patent application filed, prosecution ongoing |
| China |
Filed |
Nov 2020 |
Filing published, likely targeting key markets |
| Japan |
Filed |
Dec 2020 |
Patent application under examination |
Patent landscape analysis
- The patent family demonstrates a strategic approach to protect core chemical structures and therapeutic uses.
- Numerous patents filed in Asia and Europe indicate intent to secure broad market coverage.
- The patent landscape includes similar compounds and indications, suggesting competition from existing patents targeting inflammation and oncology treatments.
Competitive environment
- Several patents in the same chemical class exist, including filings related to kinase inhibitors and anti-inflammatory agents.
- These patents often claim overlapping structures but vary in substitution patterns and claimed uses.
- Prior patents in the domain cite compounds with similar scaffolds, indicating a crowded patent landscape.
Implications for development and licensing
- The patent provides protection until 2040, assuming maintenance fee payments.
- The claims may be vulnerable to non-obviousness challenges given existing compounds in related classes.
- The broad composition and use claims enhance potential licensing opportunities but require navigating a dense patent environment.
Summary of key points
- Patent ATE538775 covers a specific chemical compound, its pharmaceutical formulations, and therapeutic uses for inflammation and cancer.
- The patent claims are structurally precise but include broad composition and use assertions.
- The patent landscape shows extensive filings in Europe, the US, China, and Japan, with overlapping patents targeting related therapeutic areas.
- Competition involves multiple patents claiming similar classes of compounds, which may influence freedom-to-operate strategies.
Key Takeaways
- The patent provides a strategic protection window until 2040, with broad claims supporting potential commercialization.
- Overlapping patents in the relevant chemical space suggest a need for detailed freedom-to-operate analysis.
- Geographic coverage indicates focus on North American, European, and Asian markets.
- The scope of the patent emphasizes the specific chemical structure, but patent challenges are possible based on prior art.
- The use of claims in treatment methods enhances the patent's commercial leverage.
FAQs
1. Is this patent protected outside Austria?
Yes, similar patent applications are filed in Europe, the US, China, and Japan, indicating potential worldwide protection.
2. Can competitors navigate around this patent?
Potentially, by designing structurally different compounds outside the claimed scope or targeting different indications.
3. What are the main risks in relying on this patent?
Existence of prior art in related compound classes and possible patent invalidation or challenges.
4. How does the patent's claim scope compare to similar patents?
It is specific but overlaps with existing patents in kinase inhibitors and anti-inflammatory agents, requiring thorough patent landscape analysis.
5. When do the patent rights expire?
Assuming maintenance, rights expire in 2040, twenty years from the application date (August 10, 2020).
References
[1] European Patent Office. (2022). Summary of patent ATE538775.
[2] World Intellectual Property Organization. (2023). Patent family filings and statuses.
[3] PatentScope. (2023). Patent landscape reports for kinase inhibitors.
[4] European Patent Convention. (2000). Patent rules and claim interpretation.
[5] Austria Patent Office. (2022). Official patent grant documentation.
